FY2024 Earnings Estimate for Qiagen Issued By Zacks Research

Qiagen (NYSE:QGEN) – Investment analysts at Zacks Research raised their FY2024 earnings per share (EPS) estimates for shares of Qiagen in a research note issued on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the company will earn $2.17 per share for the year, up from their prior forecast of $2.14. The consensus estimate for Qiagen’s current full-year earnings is $2.18 per share. Zacks Research also issued estimates for Qiagen’s Q1 2025 earnings at $0.49 EPS, Q3 2025 earnings at $0.57 EPS, Q4 2025 earnings at $0.62 EPS, FY2025 earnings at $2.25 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.65 EPS and FY2026 earnings at $2.45 EPS.

Several other analysts have also commented on the stock. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 17th. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Qiagen currently has an average rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $43.29 on Monday. The company has a market capitalization of $9.88 billion, a P/E ratio of 111.00, a price-to-earnings-growth ratio of 3.38 and a beta of 0.35. The company’s 50-day moving average is $43.17 and its 200 day moving average is $43.66. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44.

Hedge Funds Weigh In On Qiagen

Several hedge funds have recently made changes to their positions in the stock. Massmutual Trust Co. FSB ADV grew its stake in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after acquiring an additional 243 shares in the last quarter. CWM LLC grew its position in shares of Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after purchasing an additional 269 shares in the last quarter. Zurich Insurance Group Ltd FI increased its holdings in shares of Qiagen by 5.7% in the third quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company’s stock worth $239,000 after purchasing an additional 287 shares during the period. National Bank of Canada FI raised its position in shares of Qiagen by 1.2% in the third quarter. National Bank of Canada FI now owns 25,636 shares of the company’s stock worth $1,155,000 after buying an additional 308 shares in the last quarter. Finally, Atria Investments Inc boosted its stake in Qiagen by 6.0% during the third quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock valued at $348,000 after buying an additional 433 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.